At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
LCPUFA Oil Supplement +1 moredrug
Likely dose
LCPUFA Oil Supplement 25 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fatty Acid Supplements Alter Biological Signatures in Children With Autism Spectrum Disorder
In Brief
A Phase 2 clinical trial evaluating LCPUFA Oil Supplement and Canola Oil Placebo for Autism Spectrum Disorder. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The purpose of this study is to examine how fatty acid supplementation alters biological signatures in children with ASD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder
CountriesUnited States
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJun 2018
Primary CompletionJan 2020
TodayJul 2026
First PostedJun 8, 2018
Enrollment StartJun 28, 2018
Primary CompletionJan 10, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.1 years ago
Interventions
LCPUFA Oil Supplementdrug
25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Canola Oil Placebodietary
Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days